Compare · ALHC vs NTRA
ALHC vs NTRA
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $58.35B, about 34.5x ALHC ($1.69B).
- NTRA has been more active in the news (12 items in the past 4 weeks vs 9 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Natera Inc.
- Price
- $8.30+2.03%
- $393.33-2.81%
- Market cap
- $1.69B
- $58.35B
- 1M return
- -4.54%
- -
- 1Y return
- -51.55%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ALHC
- Alignment Health Expands Medicare Advantage Coverage to San Antonio for 2027
- Alignment Healthcare to Announce Third Quarter 2026 Financial Results and Host Conference Call Thursday, Oct. 29, 2026
- Alignment Health Expands Medicare Advantage Coverage to Four New Charlotte-Area Counties for 2027
- Alignment Health Launches New Medicare Advantage Plan Designed for Asian American Seniors in Los Angeles and Orange Counties
- Alignment Healthcare downgraded by William Blair
- SEC Form 8-K filed by Alignment Healthcare Inc.
- SEC Form 4 filed by Alignment Healthcare Inc.
- Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027
- Alignment Health Expands Access to Personalized Senior Care in 2027 with New Markets, Provider Networks and Medicare Advantage Plan Options
- EVP, Corporate Affairs Konowiecki Joseph S sold $202,430 worth of shares (23,511 units at $8.61), decreasing direct ownership by 2% to 1,080,305 units (SEC Form 4) to satisfy tax liability
Latest NTRA
- SEC Form 4 filed by Natera Inc.
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)